Evidence map›Paper›PMID 35032409›Full record

ArticleInternational forum of allergy & rhinology2022

Clinical factors associated with lower health scores in COVID-19-related persistent olfactory dysfunction.

Mena Said, Thanh Luong, Sophie S Jang, Morgan E Davis, Adam S DeConde, Carol H Yan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International forum of allergy & rhinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Comparing Quality of Life in Smell and Taste Disorders With Other Chronic Conditions-A Narrative Review.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mena SaidDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, CA.
Thanh LuongDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, CA.
Sophie S JangDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, CA.
Morgan E DavisDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, CA.
Adam S DeCondeDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, CA.
Carol H YanDepartment of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, CA.
University of California, San Diego · USUniversity of San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with persistent COVID-19 olfactory dysfunction (OD) commonly report parosmia. Understanding the impact of COVID-19 OD and parosmia is critical to prioritizing research and interventions. In this study we investigate the impact of parosmia and other clinical and disease characteristics on health state utility values (HUVs) for those with persistent COVID-19 OD.

methodsPatients with a history of COVID-19 diagnosis and persistent OD were recruited from a tertiary medical center and a social media support forum for chemosensory dysfunction. Clinical characteristics and disease-specific symptoms were obtained along with self-reported history of smell function and presence of parosmia. HUVs were calculated using indirect (EuroQol 5-Dimension [EQ-5D]) and direct (VAS) measures.

resultsOur study included 286 subjects (75.52% women) with persistent COVID-19-related OD. Results (mean ± standard deviation) of HUVs based on EQ-5D and VAS were 0.81 ± 0.14 and 0.73 ± 0.21, respectively. Mean self-reported smell function (on a 0-10 scale) was 9.67 ± 1.25 pre-COVID-19, 0.93 ± 2.34 at diagnosis, and 3.39 ± 2.32 at most current assessment. A total of 89.16% of the subjects reported parosmia and 24.13% sought medical care for anosmia. Seeing an MD for OD (p < 0.001), female gender (EQ-5D only, p = 0.002), a history of chronic pain (p < 0.05) and depression/anxiety (EQ-5D only, p < 0.001) predicted worse health. Parosmia and persistent symptoms, such as shortness of breath, were associated with lower EQ-5D and VAS scores, but did not independently predict poorer health scores on multivariable analysis.

conclusionPersistent COVID-19 OD results in health states comparable to other chronic diseases.

Indexed as

COVID-19Olfaction DisordersCOVID-19 TestingFemaleHumansMaleQuality of LifeSmellCOVID-19health utility valuesparosmiapersistent olfactory dysfunctionquality of life

Identifiers

PMID35032409
PMCPMC9011709
OpenAlexW4206238417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.